Soli-Lite LG4 Galileo

K192755 · Silhouet-Tone Corporation · GEX · Dec 20, 2019 · General, Plastic Surgery

Device Facts

• Record ID: K192755
• Device Name: Soli-Lite LG4 Galileo
• Applicant: Silhouet-Tone Corporation
• Product Code: GEX · General, Plastic Surgery
• Decision Date: Dec 20, 2019
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 878.4810
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

Blue (410-415mm), is generally indicated to treat dermatological conditions and specifically indicated to treat moderate inflammatory acne vulgaris. Red (620-633nm) and Infrared (820-830nm) Combination is intended to emit energy in the red and infra-red region of the spectrum for use in dermatology for the treatment of periorbital wrinkles. Combination of Infrared (820-830mm) and Yellow (585-595mm) is intended to emit energy in the IR and visible spectrum to provide topical heating for the purpose of elevating tissue temperature; for the temporary relief of minor muscle and ioint pain, arthritis and muscle spasm; relieving stiffness; promoting the relaxation of muscle tissue; and to temporarily increase local blood circulation where applied.

Device Story

Portable phototherapy device using LEDs to emit specific light wavelengths (Red 620-633nm, Blue 410-415nm, Infrared 820-830nm, Yellow 585-595nm). System comprises base, irradiator head, and lifting stand. Operator uses interface software to control functions and irradiance levels. Device delivers light energy to skin surface; thermal effects used for pain relief/circulation; photochemical effects used for acne/wrinkles. Used in clinical settings by healthcare professionals. Output affects clinical decision-making by providing non-invasive therapeutic options for dermatological and musculoskeletal conditions.

Clinical Evidence

Bench testing only. Device performance verified through conformance to ANSI/AAMI ES60601-1, IEC60601-1-2, IEC60601-2-57, and IEC62471 standards. Software verification conducted per FDA guidance.

Technological Characteristics

Portable LED-based phototherapy system. Wavelengths: Red (620-633nm), Blue (410-415nm), Infrared (820-830nm), Yellow (585-595nm). Adjustable irradiance (4 levels). Microprocessor-controlled. Standards: IEC60601-1, IEC60601-1-2, IEC60601-2-57, IEC62471.

Indications for Use

Indicated for patients requiring treatment of moderate inflammatory acne vulgaris (blue light), periorbital wrinkles (red/infrared combination), or topical heating for temporary relief of minor muscle/joint pain, arthritis, muscle spasm, stiffness, and increased local blood circulation (infrared/yellow combination).

Regulatory Classification

Identification

(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.

Predicate Devices

• Aklarus Phototherapy System (K083183)

Reference Devices

• Healite II (K113668)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA acronym along with the full name of the agency on the right. The FDA part of the logo is in blue, with the acronym in a square and the full name, "U.S. Food & Drug Administration," written out next to it.

December 20, 2019

Silhouet-Tone Corporation Genevieve St-Jean Regulatory Affairs Specialist 1985 Michelin Laval, Quebec, Canada, H7L3T6

Re: K192755

Trade/Device Name: Soli-Lite LG4 Galileo Regulation Number: 21 CFR 878.4810 Regulation Name: Laser Surgical Instrument For Use In General And Plastic Surgery And In Dermatology Regulatory Class: Class II Product Code: GEX, ILY Dated: September 25, 2019 Received: September 30, 2019

Dear Genevieve St-Jean:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or post-marketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely.

Purva Pandya Acting Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

## Indications for Use

510(k) Number (if known)

K192755

Device Name

Soli-Lite LG4 Galileo

Indications for Use (Describe)

Blue (410-415mm), is generally indicated to treat dermatological conditions and specifically indicated to treat moderate inflammatory acne vulgaris.

Red (620-633nm) and Infrared (820-830nm) Combination is intended to emit energy in the red and infra-red region of the spectrum for use in dermatology for the treatment of periorbital wrinkles.

Combination of Infrared (820-830mm) and Yellow (585-595mm) is intended to emit energy in the IR and visible spectrum to provide topical heating for the purpose of elevating tissue temperature; for the temporary relief of minor muscle and ioint pain, arthritis and muscle spasm; relieving stiffness; promoting the relaxation of muscle tissue; and to temporarily increase local blood circulation where applied.

Type of Use (Select one or both, as applicable)

| X Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/2 description: The image shows the logo for Silhouet-Tone. The logo features a stylized swan inside of a circle above the company name. The company name is written in a sans-serif font, with a small circle to the right of the word "Tone".

Page 1 of 3

## 510(k) Summary

## 1. Submitter's Identifications

Silhouet-Tone Corporation 1985 Michelin Laval, Québec Canada, H7L 3T6

Phone: [phone] Fax: [phone]

Contact Person: Geneviève St-Jean Contact Title: Regulatory Affairs Specialist Date Revised: December 19, 2019

## 2. Name of the Device

Device Name: Soli-Lite LG4 Galileo Usual name: Phototherapy Device Classification Name: Laser surgical instrument for use in general and plastic surgery and in dermatology (21 CFR 878.4810) Regulatory Class: II Product Code: GEX, ILY

## 3. Predicate Devices

K083183 Aklarus Phototherapy System K113668 Healite II (Reference Predicate)

## 4. Device Description

The Photo-Therapy Device Soli-Lite LG4 Galileo is a portable device which uses specific wavelengths of light, produced by light emitting diodes (LEDs).

The device produces light in the following regions of the light spectrum:

- Red (620-633nm)
- Blue (410-415nm)
- Sequence of Yellow (585-595nm) and Infra-red (820-830nm) ●

This device is mainly made up of the base (main frame), the head (irradiator), and the lifting stand. The base unit contains power supply and control system. The user interface software allows the operator to access and control all device functions.

{4}------------------------------------------------

- ONE®

## 5. Indication for use

Blue (410-415nm), is generally indicated to treat dermatological conditions and specifically indicated to treat moderate inflammatory acne vulgaris.

Red (620-633nm) and Infrared (820-830nm) Combination is intended to emit energy in the red and infrared region of the spectrum for use in dermatology for the treatment of periorbital wrinkles.

Combination of Infrared (820-830nm) and Yellow (585-595nm) is intended to emit energy in the IR and visible spectrum to provide topical heating for the purpose of elevating tissue temperature; for the temporary relief of minor muscle and joint pain, arthritis and muscle spasm; relieving stiffness; promoting the relaxation of muscle tissue; and to temporarily increase local blood circulation where applied.

## 6. Summary of Substantial Equivalence

| | Soli-Lite | Aklarus Phototherapy System | Healite II |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 510k Number | K192755 | K083183 | K113668 |
| Product Code | GEX, ILY | GEX, ILY | ILY |
| Indications for use | Blue (410-415nm), is generally<br>indicated to treat dermatological<br>conditions and specifically<br>indicated to treat moderate<br>inflammatory acne vulgaris.<br>Red (620-633nm) and Infrared<br>(820-830nm) Combination is<br>intended to emit energy in the red<br>and infra-red region of the<br>spectrum for use in dermatology<br>for the treatment of periorbital<br>wrinkles.<br>Combination of Infrared (820-<br>830nm) and Yellow (585-595nm) is<br>intended to emit energy in the IR<br>and visible spectrum to provide<br>topical heating for the purpose of<br>elevating tissue temperature; for<br>the temporary relief of minor<br>muscle and joint pain, arthritis and<br>muscle spasm; relieving stiffness;<br>promoting the relaxation of muscle<br>tissue; and to temporarily increase<br>local blood circulation where<br>applied. | Blue (420nm±10nm), is generally<br>indicated to treat dermatological<br>conditions and specifically indicated to<br>treat moderate inflammatory acne<br>vulgaris.<br>Combination of Red (628nm ±10nm)<br>and Blue (420nm ±10nm) is intended<br>to emit energy in the red, blue regions<br>of the spectrum to treat dermatological<br>conditions, specifically indicated to treat<br>mild to moderate acne vulgaris.<br>Anti-Aging Red (628nm ±10nm) and<br>Anti-Aging Infrared (880nm±10nm)<br>Combination is intended to emit energy<br>in the red and infra-red region of the<br>spectrum for use in dermatology for the<br>treatment of periorbital wrinkles.<br>Infrared (880nm ±10nm) is intended<br>to emit energy in the IR spectrum to<br>provide topical heating for the purpose<br>of elevating tissue temperature; for the<br>temporary relief of minor muscle and<br>joint pain, arthritis and muscle spasm;<br>relieving stiffness; promoting the<br>relaxation of muscle tissue; and to<br>temporarily increase local blood<br>circulation where applied. | For use in temporary<br>relief of minor muscle<br>and joint pain, arthritis<br>and muscle spasm;<br>relieving stiffness;<br>promoting the<br>relaxation of muscle<br>tissue and to<br>temporarily increase<br>local blood circulation<br>where applied |
| Configuration | Portable | Portable | Portable |
| Components | Main frame, irradiator, lifting stand | Main frame, irradiator, lifting stand | Main frame, irradiator |
| Wavelength | Red 620-633nm<br>Blue 410-415nm<br>Infrared 820-830nm/ Yellow 585-<br>595nm | Red 628nm±10nm<br>Blue 420nm±10nm<br>Infrared 880nm±10nm | Infrared 830nm/<br>Yellow 590nm |

{5}------------------------------------------------

| SILHOUET-TONE® |
|----------------|

| Effective irradiance | Adjustable: 4 levels<br>Red: 19-47mW/cm²<br>Blue: 25-40mW/cm²<br>Infrared/yellow: 29-61mW/cm² | Red 43mW/cm²<br>Blue 22mW/cm²<br>Infrared: 35mW/cm² | Adjustable: 2 levels<br>Infrared/yellow: 27-<br>65mW/cm² |
|------------------------|-----------------------------------------------------------------------------------------------|---------------------------------------------------------|----------------------------------------------------------|
| Operation interface | Display screen | Display screen | Display screen |
| Operation Mode | Continuous operation | Continuous operation | Continuous operation |
| Standard | IEC60601-1<br>IEC60601-1-2<br>IEC60601-2-57<br>IEC62471 | IEC60601-1<br>IEC60601-1-2<br>IEC60601-2-57<br>IEC62471 | Unknown |
| Microprocessor Control | yes | yes | yes |

## 7. Substantial Equivalence

The proposed device has similar classification information, intended use, product design, and specifications as the Aklarus Phototherapy System.

Wavelengths are similar to the Aklarus Phototherapy System.

The most significant difference is the effective irradiance of the blue light between Soli-Lite LG4 Galileo and Aklarus Phototherapy System. These differences do not influence the effectiveness and safety of the device. According to the nonclinical test results, the proposed device is as effective and perform as well as the predicate device.

## 8. Performance Data

The following testing was performed on the Soli-Lite Galileo in accordance with the requirements of the design control regulations and established quality assurance procedures.

ANSI/AAMI ES60601-1:2005/(R)2012 and A1:2012, C1:2009/(R)2012 and A2:2010/(R)2012 Medical electrical equipment-Part 1: General requirements for basic safety and essential performance

IEC60601-1-2:2014 Medical electrical equipment- Electromagnetic compatibility requirements

IEC60601-2-57:2011 Medical Electrical Equipment-Part 2-57: Particular requirements for the basic safety and essential performance of non-laser light source equipment intended for therapeutic, diagnostic, monitoring and cosmetic/aesthetic use

IEC62471:2006 Photobiological safety of lamps and lamp systems

In addition to conformance with voluntary standards, the software verification has been carried out according to the FDA Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices.

# 9. Conclusion

Based upon the performance data, the subject device is determined to be substantially equivalent to the predicate device Aklarus Phototherapy System K083183.